ABOUT CITELINE
Citeline powers a full suite of complementary business intelligence offerings to meet the evolving needs of health care professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial and regulatory-related decisions and create real-world opportunities for growth.
Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more.
FEATURED CONTENT
-
Drug development experts remain intent on pharma’s prospects, especially in China, which have overtaken the US in first-time new drugs and continues to nurture a robust pipeline.
-
Recruiting for rare disease clinical trials is daunting, and making patients aware of clinical trials, involving them in trial design, and building trust are a few ways sponsors can boost recruitment.
-
Another SCOPE Summit is in the record books, and it was jam-packed with informative sessions. Themes included patient-centricity, AI (no surprise here), patient recruitment, and much more.
-
Multiple AI use cases with significant impact have been identified, and they are expected to drive innovations in clinical trials, precision medicine, and commercial operations.
-
Learn how to create a direct line from clinical planning and protocol design to clinical trial disclosure to optimize efficiency across the entire trial lifecycle.
-
AI is only as good as the data it’s built upon. Our customized AI platforms are constructed on a foundation of trustworthy, carefully curated data to produce detailed, expert-driven responses.
-
Experts predict 2026 trends: more pragmatic trial design, expanded use of data and AI for patient matching, and registration and reporting of results for all human trials.
-
The data underlying strategic decisions made by clinical teams often remain fragmented, backward-looking, or insufficiently validated. These teams need decision-ready data that brings clarity where it matters most.
-
This use case shows how sponsors can gain clarity on disclosure requirements when entering a new country.
-
Building patient trust fuels engagement, data and technology enable targeted recruitment, and real-time patient identification with consistent support drives scalable enrollment success.
-
Clinical trial starts grew 5.5% to 10,503 in 2024, a slowdown from 2023’s 9.4% rise in trial starts. Sustained geopolitical and global regulatory pressures on pharma contributed to curbing momentum.
-
A mid-sized contract research organization (CRO) sought help with writing clinical trial diversity action plans and assessing feasibility for therapeutic areas outside its usual scope.
-
Recruiting the right patients into a clinical trial is only half the battle. To combat attrition, sponsors must also institute measures that ensure patients remain comfortable and confident throughout the trial.
-
Q3 2025 brought notable progress across the gene, cell, and RNA therapy landscape, marked by four new global approvals. While regulatory progress continued, clinical development activity slowed.
-
Identifying and enrolling the right-fit patients from the outset is essential, but so is implementing comprehensive retention strategies that prioritize patient comfort, trust, and ongoing engagement.
-
The updated ICH GCP guideline modernizes clinical trial standards, aligning with today’s technologies to enhance participant safety, data integrity, and risk-based trial design.
-
Noncompliance with clinical trial disclosure regulations can jeopardize M&A deals. Understanding FDA and SEC requirements is critical to avoid red flags during due diligence.
-
Health literacy gaps and online misinformation hinder clinical trial recruitment. Meeting patients where they are — digitally and educationally — can improve engagement and enrollment success.
-
Support groups offer emotional strength and connection for patients and caregivers, helping them navigate medical challenges, treatment journeys, and the complexities of chronic conditions.
-
AI has quietly embedded itself into the operational heart of clinical development, where it is accelerating decisions, reducing manual burden, and improving outcomes.
CONTACT INFORMATION
Citeline
605 Third Ave.
New York, NY 10158
UNITED STATES
Phone: 1 212-600-3530
Contact: Steven Horlock
FEATURED SOLUTIONS
- Managing Execution Of A Phase III Clinical Trial
- Accelerate Enrollment And Reduce Site Burden
- How AI Is Setting A New Standard In Clinical Development
- A New Blueprint For Transforming Feasibility And Recruitment
- No Statistically Significant Progress — Yet
- Community Trust Can't Be Outsourced
- What Bright Spots In Trial Diversity Are Doing Differently
- The Real Story Behind SOGI Data In Clinical Trials
- Health Equity Isn't A Buzzword — It's A Business Imperative
- TrialScope Disclose: Plan With Purpose, Disclose With Confidence
- AI Importer — See It in Action!
- Support For Complex Regulatory Documents
- Smarter, More Accurate Patient Matching Enhances Trial Efficiency
- Precision Recruitment Is the Name of the Game
- Get To Know Citeline Clinical Solutions
FEATURED WEBINARS
-
As regulatory authorities and industry stakeholders increasingly prioritize accessible communication, PLS are becoming not only a best practice but, in many regions, an emerging requirement.
-
Data quality and governance underpin portfolio, clinical trial, and commercial decisions. Combined with trustworthy, explainable AI, they enable complete insights for optimization, feasibility, forecasting, and planning.
-
Explore key changes to the guidelines and how they're transforming clinical trials with a focus on patient centricity, digital innovation, and risk-based quality management.
-
Discover how integrating independent, holistic data with precision feasibility strategies can transform site enablement and patient recruitment to unlock new levels of trial success.
-
Navigating the Clinical Trial Registry Ecosystem — Regional and Global Registry Selection provides harmonization initiatives to improve transparency and data consistency across registries.
-
Learn how the updated ICH GCP E6(R3) guidelines are transforming clinical trials with a focus on patient centricity, digital innovation, and risk-based quality management.
-
Failing to comply with disclosure rules can leave sponsors open to fines and penalties. Here, we present the latest disclosure requirements, enforcement mechanisms, and tips on how best to stay compliant.
-
Plain language summaries (PLS) are growing in importance as a requirement in global transparency. Focusing on protocol and results summaries, we cover expectations and best practices for global PLS implementation.
-
Gaining a patient’s trust is the first step to trial participation. Find out how to address this in From Cautious to Committed, the first of a three-part webinar series covering strategies across the patient recruitment continuum.
-
In the final session of our three-part webinar series, we explore what this next phase of evolution means for clinical trial planning and execution, and examine how innovative approaches are reshaping recruitment strategies from the ground up.